The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.

Filipe FerrariVítor M MartinsRafael S ScheffelAnderson D da SilveiraMarcelo Trotte MottaEmilio H MoriguchiRaul D SantosRicardo Stein

Published in: The Annals of pharmacotherapy (2021)

SGLT2 inhibitor therapy reduces CV death and hospitalizations in HFrEF patients regardless of T2DM. The decision to prescribe this class of drugs should not be determined by glycemic status.

Keyphrases

cardiovascular disease
type diabetes
end stage renal disease
glycemic control
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
stem cells
decision making
coronary artery disease
patient reported outcomes
cell therapy
bone marrow
weight loss
smoking cessation